Zurich-Schlieren, Switzerland, July 6, 2021 - Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, today announced that the group of Prof. J Morote Robles from the Vall d’Hebron University Hospital in Barcelona, Spain will present their clinical study results of Proclarix® in combination with MRI for improved prostate cancer diagnosis at the virtual Annual EAU Congress, as follows:
Poster Session 35: Prostate cancer screening, biopsy indication protocols and markers – Monday, July 12, 2021, 11:30 AM-12:30 PM.
Abstract P1011 – Retrospective evaluation of Proclarix as a companion to mpMRI for the detection of clinically significant prostate cancer.
Abstract P1017 – Retrospective evaluation of Proclarix for the detection of clinically significant prostate cancer together with mpMRI
Presenter: M. Campistol Torres, Universitat Autònoma de Barcelona, Vall d’Hebron University Hospital, Barcelona, Spain.
The two posters highlight the fact that Proclarix® can be used with high confidence in routine practice. The risk of missing clinically significant cancer was 5% or lower. With an NPV of 94% Proclarix reliably rules out patients with no or insignificant cancer. Performance of Proclarix was better than %fPSA, PSA density and risk calculators with, at equal sensitivity, higher specificity, PPV and higher reduction of unneeded biopsies with a clinically relevant saving of one out of three unneeded biopsies. In addition, it was demonstrated that Proclarix can even be safely used in men with an extended range of elevated PSA up to 20 ng/ml, disregard of DRE status or prostate volume.
When Proclarix was combined with MRI into a single score, no or indolent cancers were ruled out with significantly better performance than PSA density or PI-RADS score alone and significantly higher reduction of up to 3 out of 4 unneeded biopsies was achieved.
Proclarix® is CE-IVD marked and indicated for prostate cancer diagnosis in patients with normal digital rectal exam (DRE), enlarged prostate volume and elevated levels of PSA at 2-10 ng/ml. Proclarix is a risk score combining in-vitro assays for the quantitative detection of biomarkers with a proprietary algorithm to assess a patient’s risk of having clinically significant prostate cancer. Detection of prostate cancer-related biomarkers in blood serum using the Proclarix risk score has been demonstrated in multiple clinical studies to be a reliable indicator of the presence of clinically significant prostate cancer.
Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnosis. The company has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The lead product Proclarix® is a blood based prostate cancer test panel and risk score currently available in Europe. Proteomedix is located in the Bio-Technopark of Zurich-Schlieren, Switzerland. For more information, visit www.proteomedix.com.
For further details, please contact:
Dr. Ralph Schiess, CSO
email@example.com, +41 44 733 40 90